In conclusion, our study found the associated risks of acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke were higher following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. The gene discussed is CYP3A4; the disease is myocardial infarction.